FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Soraya Kharboutli
List of publications:
BibTeX-Download
Medizinische Fakultät
Publications
(11)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Inferior Outcomes of EU Versus US Patients Treated with CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use (2023)
Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al.
Journal article
CD19-targeted CAR T cells in refractory antisynthetase syndrome (2023)
Müller F, Böltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, et al.
Journal article
Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma (2023)
Zundler S, Vitali F, Kharboutli S, Völkl S, Polifka I, Mackensen A, Atreya R, et al.
Journal article
Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. (2023)
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al.
Journal article, Erratum
Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection (2022)
Buecklein VL, Perez-Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al.
Conference contribution
CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients (2022)
Müller F, Völkl S, Mougiakakos D, Böltz S, Aigner M, Gary R, Kretschmann S, et al.
Conference contribution
CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus (2022)
Schett G, Böltz S, Müller F, Kleyer A, Völkl S, Aigner M, Gary R, et al.
Conference contribution
CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS (2022)
Schett G, Böltz S, Müller F, Kleyer A, Völkl S, Aigner M, Gary R, et al.
Conference contribution
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus (2022)
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al.
Journal article
CD19-targeted CAR T cells in refractory systemic lupus erythematosus (2021)
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, et al.
Journal article
‹
1
2
›